文献速递心境障碍精神分裂症与精神病性障碍儿童青少年精神

妊娠早期暴露喹硫平后婴儿重大畸形风险

Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine.
PubMed 文献 · Am J Psychiatry · 2018-08-16

该研究基于美国非典型抗精神病药妊娠登记处的前瞻性数据,比较妊娠早期暴露喹硫平与无第二代抗精神病药暴露的精神疾病史孕妇的婴儿重大畸形风险。结果显示暴露组畸形率为1.3%,对照组为1.4%,未调整比值比为0.90(95%CI=0.15, 5.46),提示风险与对照相当,但样本量小、置信区间宽。

要点

  • 妊娠早期喹硫平暴露婴儿重大畸形率为1.3%,未暴露组为1.4%。
  • 未调整OR为0.90(95%CI=0.15, 5.46),与对照无显著差异。
  • 置信区间上限未超过5倍风险,结果令人安心但需更大样本验证。

核心结论

  • 妊娠早期暴露喹硫平后婴儿重大畸形风险与无第二代抗精神病药暴露的精神疾病史孕妇的婴儿相当。

研究设计与样本

  • 美国非典型抗精神病药妊娠登记处前瞻性队列研究,孕妇年龄18-45岁,妊娠期及产后访谈,医学记录由盲法畸形学专家裁定。

主要发现

  • 截至2017年3月,888名孕妇入组,357名符合分析条件;暴露组152名孕妇(155名婴儿,含3对双胞胎),对照组205名孕妇(210名婴儿,含5对双胞胎)。
  • 暴露组确认2例重大畸形(1.3%),对照组确认3例重大畸形(1.4%)。
  • 未调整比值比为0.90(95%CI=0.15, 5.46),与现有对照数据的合并估计一致。

关键数值与推荐

  • 重大畸形率:暴露组1.3%(2/155),对照组1.4%(3/210)。
  • 未调整OR=0.90(95%CI=0.15, 5.46)。

临床怎么用

  • 对于有精神疾病史的育龄期女性,妊娠早期使用喹硫平未显示增加重大畸形风险,可作为用药决策的参考。

局限性

  • 样本量小,置信区间宽,未来需持续收集数据以获得更精确估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Second-generation antipsychotics are commonly prescribed to reproductive-age women for the treatment of a spectrum of psychiatric disorders. Quetiapine is the most commonly prescribed medication in this class, and therefore a better understanding of its reproductive safety profile is critical. The goal of this study was to determine the risk of major malformations among infants exposed to quetiapine during pregnancy compared with a group of infants whose mothers had a history of psychiatric morbidity but who did not use a second-generation antipsychotic during pregnancy. METHOD: The National Pregnancy Registry for Atypical Antipsychotics interviews pregnant women ages 18-45 during pregnancy and the postpartum period. Obstetric, labor, and delivery medical records and pediatric medical records from the first 6 months of life were screened for evidence of major malformations, followed by adjudication by a blinded dysmorphologist. Women with first-trimester exposure to quetiapine were compared with control subjects without exposure to second-generation antipsychotics. RESULTS: As of March 2017, 888 women had enrolled prospectively and 357 were eligible for analysis. Of these, 152 women with first-trimester exposure to quetiapine were compared with 205 control subjects without any second-generation antipsychotic exposure. For the 155 infants born to women in the exposed group (including three sets of twins), two major malformations were confirmed (1.3%), compared with three major malformations among the 210 infants born in the unexposed group (including five sets of twins) (1.4%). The unadjusted odds ratio for major malformations between infants with and without quetiapine exposure was 0.90 (95% CI=0.15, 5.46), which is consistent with the pooled estimate of the available controlled data on fetal exposure to quetiapine. CONCLUSIONS: These data regarding the safety of fetal exposure to quetiapine in a small sample of well-characterized participants are reassuring given that the confidence interval does not exceed a fivefold increased risk of major malformations relative to psychiatric control subjects. Future analyses based on ongoing data collection will produce more precise estimates.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cohen LS, Góez-Mogollón L, Sosinsky AZ, et al. Risk of Major Malformations in Infants Following First-Trimester Exposure to Quetiapine. Am J Psychiatry. 2018. PMID: 30111186. doi:10.1176/appi.ajp.2018.18010098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。